Stem definition | Drug id | CAS RN |
---|---|---|
928 | 97-77-8 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 24.09 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 28, 1951 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psychiatric symptom | 117.52 | 41.14 | 25 | 916 | 4545 | 50599638 |
Intentional self-injury | 111.25 | 41.14 | 33 | 908 | 23079 | 50581104 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Milk-alkali syndrome | 124.68 | 36.88 | 22 | 1576 | 500 | 29572429 |
Alcohol intolerance | 103.40 | 36.88 | 18 | 1580 | 377 | 29572552 |
Psychiatric symptom | 65.98 | 36.88 | 18 | 1580 | 3166 | 29569763 |
Drug abuse | 56.04 | 36.88 | 41 | 1557 | 79842 | 29493087 |
Metabolic alkalosis | 55.65 | 36.88 | 13 | 1585 | 1223 | 29571706 |
Hypercalcaemia | 48.16 | 36.88 | 20 | 1578 | 12739 | 29560190 |
Hypertonia neonatal | 45.33 | 36.88 | 9 | 1589 | 391 | 29572538 |
Drug interaction | 41.59 | 36.88 | 52 | 1546 | 197333 | 29375596 |
Depressed level of consciousness | 37.83 | 36.88 | 24 | 1574 | 36918 | 29536011 |
Sopor | 37.45 | 36.88 | 16 | 1582 | 10918 | 29562011 |
Intentional overdose | 36.91 | 36.88 | 24 | 1574 | 38504 | 29534425 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psychiatric symptom | 181.23 | 33.07 | 43 | 2395 | 6230 | 64490064 |
Alcohol intolerance | 116.77 | 33.07 | 19 | 2419 | 379 | 64495915 |
Milk-alkali syndrome | 114.33 | 33.07 | 22 | 2416 | 1171 | 64495123 |
Intentional self-injury | 105.23 | 33.07 | 40 | 2398 | 29004 | 64467290 |
Drug abuse | 89.70 | 33.07 | 58 | 2380 | 132316 | 64363978 |
Sopor | 60.16 | 33.07 | 27 | 2411 | 29634 | 64466660 |
Off label use | 58.20 | 33.07 | 93 | 2345 | 632713 | 63863581 |
Drug interaction | 53.69 | 33.07 | 67 | 2371 | 362016 | 64134278 |
Intentional overdose | 52.57 | 33.07 | 36 | 2402 | 89908 | 64406386 |
Metabolic alkalosis | 45.32 | 33.07 | 13 | 2425 | 3915 | 64492379 |
Hypercalcaemia | 37.74 | 33.07 | 20 | 2418 | 31396 | 64464898 |
Psychotic disorder | 35.94 | 33.07 | 20 | 2418 | 34558 | 64461736 |
Generalised tonic-clonic seizure | 35.91 | 33.07 | 21 | 2417 | 39836 | 64456458 |
None
Source | Code | Description |
---|---|---|
ATC | N07BB01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in alcohol dependence |
ATC | P03AA04 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES Sulfur containing products |
ATC | P03AA54 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES Sulfur containing products |
FDA MoA | N0000000183 | Acetyl Aldehyde Dehydrogenase Inhibitors |
CHEBI has role | CHEBI:24127 | fungicides |
CHEBI has role | CHEBI:35487 | aldehyde dehydrogenase (NAD) inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:37733 | EC 3.1.1.8 inhibitor |
CHEBI has role | CHEBI:48422 | angiogenesis antagonist |
CHEBI has role | CHEBI:50276 | topoisomerase I inhibitors |
CHEBI has role | CHEBI:68495 | Type I cell-death inducers |
CHEBI has role | CHEBI:73240 | NF-kappaB inhibitors |
CHEBI has role | CHEBI:78444 | Alpha-carboxylesterase inhibitor |
CHEBI has role | CHEBI:173085 | ferroptosis inducers |
MeSH PA | D065086 | Acetaldehyde Dehydrogenase Inhibitors |
MeSH PA | D000427 | Alcohol Deterrents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
FDA EPC | N0000175679 | Aldehyde Dehydrogenase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Alcoholism | indication | 7200002 | |
Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
Chronic glomerulonephritis | contraindication | 20917003 | |
Alcohol intoxication | contraindication | 25702006 | |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Nephritis | contraindication | 52845002 | DOID:10952 |
Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
Psychotic disorder | contraindication | 69322001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Cognitive Impairment following Traumatic Brain Injury | contraindication |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Aldehyde dehydrogenase, mitochondrial | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
Sodium/nucleoside cotransporter 1 | Transporter | Ki | 5.24 | DRUG MATRIX | |||||
Mu-type opioid receptor | GPCR | Ki | 5.85 | DRUG MATRIX | |||||
Translocator protein | Transporter | WOMBAT-PK | |||||||
D(1A) dopamine receptor | GPCR | Ki | 5.97 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.12 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.74 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 4.16 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 4.66 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.43 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.43 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 6.70 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 5.96 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.61 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 4.86 | DRUG MATRIX | |||||
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 5.32 | DRUG MATRIX | |||||
C-C chemokine receptor type 5 | GPCR | Ki | 4.74 | DRUG MATRIX | |||||
C-X-C chemokine receptor type 2 | GPCR | Ki | 5.38 | DRUG MATRIX | |||||
C-C chemokine receptor type 2 | GPCR | Ki | 6.02 | DRUG MATRIX | |||||
Mitogen-activated protein kinase 3 | Kinase | IC50 | 5.82 | DRUG MATRIX | |||||
C-C chemokine receptor type 4 | GPCR | Ki | 5.36 | DRUG MATRIX | |||||
Monoglyceride lipase | Enzyme | IC50 | 5.90 | CHEMBL | |||||
Protein-lysine 6-oxidase | Enzyme | IC50 | 6.50 | CHEMBL | |||||
Lysine-specific demethylase 5A | Enzyme | IC50 | 5 | CHEMBL | |||||
Lysyl oxidase homolog 3 | Enzyme | IC50 | 7.03 | CHEMBL | |||||
Lysyl oxidase homolog 4 | Enzyme | IC50 | 7.23 | CHEMBL | |||||
Histone-lysine N-methyltransferase EHMT2 | Enzyme | IC50 | 6.22 | CHEMBL | |||||
Histone-lysine N-methyltransferase EHMT1 | Enzyme | IC50 | 5.80 | CHEMBL | |||||
Lysyl oxidase homolog 2 | Enzyme | IC50 | 6.82 | CHEMBL | |||||
Gasdermin-D | Unclassified | IC50 | 6.40 | CHEMBL | |||||
Fructose-1,6-bisphosphatase 1 | Enzyme | IC50 | 6.22 | CHEMBL | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 4.79 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.67 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 4.33 | DRUG MATRIX | |||||
Aldehyde dehydrogenase, mitochondrial | Enzyme | IC50 | 4.40 | CHEMBL | |||||
Bifunctional protein GlmU | Enzyme | IC50 | 4.07 | CHEMBL | |||||
Gasdermin-D | Unclassified | IC50 | 6.40 | CHEMBL | |||||
Carbamate kinase, EC 2.7.2.2 | Unclassified | IC50 | 6.22 | CHEMBL |
ID | Source |
---|---|
4018494 | VUID |
N0000146816 | NUI |
D00131 | KEGG_DRUG |
3554 | RXNORM |
4018494 | VANDF |
C0012772 | UMLSCUI |
CHEBI:4659 | CHEBI |
CHEMBL964 | ChEMBL_ID |
DB00822 | DRUGBANK_ID |
D004221 | MESH_DESCRIPTOR_UI |
3117 | PUBCHEM_CID |
7168 | IUPHAR_LIGAND_ID |
1781 | INN_ID |
TR3MLJ1UAI | UNII |
2848 | MMSL |
4623 | MMSL |
d01389 | MMSL |
000752 | NDDF |
387212009 | SNOMEDCT_US |
39516004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0356 | TABLET | 250 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0357 | TABLET | 500 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-028 | TABLET | 250 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-029 | TABLET | 500 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-607 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
Antabuse | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5034 | TABLET | 250 mg | ORAL | ANDA | 18 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-196 | TABLET | 250 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-431 | TABLET | 250 mg | ORAL | ANDA | 13 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-432 | TABLET | 500 mg | ORAL | ANDA | 13 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-171 | TABLET | 250 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-172 | TABLET | 500 mg | ORAL | ANDA | 17 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2694 | TABLET | 250 mg | ORAL | ANDA | 17 sections |